FacebookTwitterGoogle+RedditEmail

The Inconvenient Senator Grassley

The “bully tactics” and “intimidation” of drug industry operatives could cause “thousands of additional cancer deaths,” cries an angry doctor in a May 29 oped in the Wall Street Journal.

But Mark O. Thornton, MD, MPH, PhD, is not talking about the lobbyists and reps embedded in doctors’ and lawmakers’ offices even as patients and constituents wait for access.

He’s talking about Sen. Charles Grassley (R., Iowa), ranking member of the Senate Finance Committee.

You see, even though “Mr. Grassley did some good after the Vioxx episode, by focusing on the woeful manner in which postmarketing drug safety is managed and regulated by the FDA,” writes Thornton, who the Journal identifies as a former medical officer in the Office of Oncology Products at the FDA who “volunteers as president of the Sarcoma Foundation of America,” the Senator “and his staff should have kept their eyes on the ball.”

Instead, Grassley wants the Government Accountability Office to investigate why the cancer drug Avastin was approved for use in metastatic breast cancer two months after the FDA’s Oncologic Drugs Advisory Committee (ODAC) rejected approval–and on the basis of data that showed improvement in PFS–progression free survival, the period of time a patient doesn’t get worse–but no improvement in overall survival.

Even drug reps were surprised it was approved.

“Not going to happen on basis of data presented to date,” posted an anonymous salesman on industry chatroom cafepharma when approval rumors first surfaced. “Think about it. What is the label going to say? Improvement in PFS but not sure of clinical relevance of this. No improvement in overall survival. FDA is not going to do it.”

Just because Vioxx caused 27,000 cardiac deaths, Avandia was found to increase cardiovascular death risk by 64 percent and Vytorin proved worthless in improving cardiovascular health all after approval, “The senator is demanding a full-scale review of each and every product ever approved,” whines Thornton, “to ensure that drugs approved on surrogate endpoints are both safe and effective.”

Imagine that.

Of course surrogate endpoints–short-term criteria a clinical study is judged on in lieu of mortality or survival data–vaulted to national fame when Merck and Schering-Plough sought to alter theirs in the suppressed ENHANCE study to keep Vytorin from looking like a national con job.

Surrogate endpoints spell Ka-Ching to the drug industry because it can start blitzing a drug while safety data is still out and Wall Street is sitting up and listening.

And if the drug turns South as it’s used by the first patients/guinea pigs, it’s cheaper to ask for forgiveness than permission; Merck, after all still made money on Vioxx despite its $4.85 billion settlement with tens of thousands of plaintiffs.

But the problem with surrogate endpoints is: your actual mileage may vary.

Vytorin reduced LDL but didn’t clear arteries.

Avandia lowered blood sugar but raised not lowered heart attack risk.

New osteoporosis drugs stop bone turnover but cause instead of prevent fractures. Oops.

Thornton served on the clinical review team for Erbitux® while at the FDA–the cancer drug at the heart of the Martha Stewart/ImClone scandal–and worries that “a change toward the much stricter endpoint of overall survival,” (sic) will chill innovation.

“U.S. cancer-drug development stands on a precipice overlooking a new dark age in which each new product’s development is longer and costlier than the last,” he writes.

Each new cancer drug is costlier, too, say health policy watchers.

Why does Erbitux® costs $17,000 a month? Avastin $4,400 a month?

Because the drug companies can get away with charging that much writes Robert Bazell, Chief science and health correspondent with NBC news, adding that if Avastin is added to the regimen for treating advanced colon cancer it would add $1.5 billion a year in new national health costs.

In a letter responding to Thornton’s oped– unsubtly titled Grassley’s War on Cancer Patients– Sen. Grassley says Thornton “mischaracterized” the GAO review and that it is an attempt “to make the relationship between the FDA and drug makers less cozy.”

He also observes that in addition to “volunteering as president of the Sarcoma Foundation of America,” Thornton is the Senior Vice President of Product Development at GenVec, Inc. which makes cancer drugs–a simple Google vett the Wall Street Journal didn’t include.

Thornton also served as Chief Medical Officer and Head of Product Development of Ziopharm Oncology Inc. and Managing Director of Clinical and Regulatory Affairs of Angiotech Pharmaceuticals and is on the Board of Directors of the partially drug industry funded Center for Medicine in the Public Interest (CMPI).

But maybe those are his career’s surrogate endpoints.

Disclosure composure

Dear Ms. Rosenberg,

I appreciate and respect your point of view raised in your piece. Indeed in my advocacy pieces, I do not mention the various companies I have worked for, since to do so would presuppose that they share my personal views. While fair to them, I fully understand how easy it is to believe that evil motives are at work in such a position.

It is unfortunate that we live in a time of such deep mistrust of motives of individuals. I consider my advocacy on behalf of cancer patients to be bipartisan and centrist, and engage often with advocactes on both ends of the political spectrum.

At any rate, I hope that through all the easy shots you took at all the fish in my barrel, one could appreciate that my views are not totally corrupted, and to perhaps consider the peril we may very well be in in being able to get new therapies out there for cancer patients.

Regarding profits in this industry, any bipartisan measures that you feel would help curb the profiteering going on in the industry when new cancer therapies get approved, I would surely support and mention to my fellow cancer advocates.

My best to you,

Mark Thornton

MARTHA ROSENBERG is staff cartoonist on the Evanston Roundtable. She can be reached at mrosenberg@evmark.org

Your Ad Here
 

 

 

 

 

More articles by:

Martha Rosenberg is an investigative health reporter. She is the author of  Born With A Junk Food Deficiency: How Flaks, Quacks and Hacks Pimp The Public Health (Prometheus).

November 20, 2018
John Davis
Geographies of Violence in Southern California
Anthony Pahnke
Abolishing ICE Means Defunding it
Maximilian Werner
Why (Mostly) Men Trophy Hunt: a Biocultural Explanation
Masturah Alatas
Undercutting Female Circumcision
Jack Rasmus
Global Oil Price Deflation 2018 and Beyond
Geoff Dutton
Why High Technology’s Double-Edged Sword is So Hard to Swallow
Binoy Kampmark
Charges Under Seal: US Prosecutors Get Busy With Julian Assange
Rev. William Alberts
America Fiddles While California Burns
Forrest Hylton, Aaron Tauss and Juan Felipe Duque Agudelo
Remaking the Common Good: the Crisis of Public Higher Education in Colombia
Patrick Cockburn
What Can We Learn From a Headmaster Who Refused to Allow His Students to Celebrate Armistice Day?
Clark T. Scott
Our Most Stalwart Company
Tom H. Hastings
Look to the Right for Corruption
Edward Hunt
With Nearly 400,000 Dead in South Sudan, Will the US Finally Change Its Policy?
Thomas Knapp
Hypocrisy Alert: Republicans Agreed with Ocasio-Cortez Until About One Minute Ago
November 19, 2018
David Rosen
Amazon Deal: New York Taxpayers Fund World Biggest Sex-Toy Retailer
Sheldon Richman
Art of the Smear: the Israel Lobby Busted
Chad Hanson
Why Trump is Wrong About the California Wildfires
Dean Baker
Will Progressives Ever Think About How We Structure Markets, Instead of Accepting them as Given?
Robert Fisk
We Remember the Great War, While Palestinians Live It
Dave Lindorff
Pelosi’s Deceptive Plan: Blocking any Tax Rise Could Rule Out Medicare-for-All and Bolstering Social Security
Rick Baum
What Can We Expect From the Democrat “Alternative” Given Their Record in California?
Thomas Scott Tucker
Trump, World War I and the Lessons of Poetry
John W. Whitehead
Red Flag Gun Laws
Newton Finn
On Earth, as in Heaven: the Utopianism of Edward Bellamy
Robert Fantina
Shithole Countries: Made in the USA
René Voss
Have Your Say about Ranching in Our Point Reyes National Seashore
Weekend Edition
November 16, 2018
Friday - Sunday
Jonah Raskin
A California Jew in a Time of Anti-Semitism
Andrew Levine
Whither the Melting Pot?
Joshua Frank
Climate Change and Wildfires: The New Western Travesty
Nick Pemberton
The Revolution’s Here, Please Excuse Me While I Laugh
T.J. Coles
Israel Cannot Use Violent Self-Defense While Occupying Gaza
Rob Urie
Nuclear Weapons are a Nightmare Made in America
Paul Street
Barack von Obamenburg, Herr Donald, and Big Capitalist Hypocrisy: On How Fascism Happens
Jeffrey St. Clair
Roaming Charges: Fire is Sweeping Our Very Streets Today
Aidan O'Brien
Ireland’s New President, Other European Fools and the Abyss 
Pete Dolack
“Winners” in Amazon Sweepstakes Sure to be the Losers
Richard Eskow
Amazon, Go Home! Billions for Working People, But Not One Cent For Tribute
Ramzy Baroud
In Breach of Human Rights, Netanyahu Supports the Death Penalty against Palestinians
Brian Terrell
Ending the War in Yemen- Congressional Resolution is Not Enough!
John Laforge
Woolsey Fire Burns Toxic Santa Susana Reactor Site
Ralph Nader
The War Over Words: Republicans Easily Defeat the Democrats
M. G. Piety
Reading Plato in the Time of the Oligarchs
Rafael Correa
Ecuador’s Soft Coup and Political Persecution
Brian Cloughley
Aid Projects Can Work, But Not “Head-Smacking Stupid Ones”
David Swanson
A Tale of Two Marines
FacebookTwitterGoogle+RedditEmail